Regeneron Pharmaceuticals, Inc. 13F Holdings · Q2 2026
Regeneron Pharmaceuticals, Inc. reported 3 securities worth $177.22M in its SEC 13F filing for Q2 2026 (period ended 2026-06-30). Top holdings: PBLS (64.35%), NTLA (35.35%), ACET (0.30%). Among its top 25 positions this quarter: 2 new, 1 exited.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | PBLS | Parabilis Medicines, Inc. | $114.0M | 64.35% | 4.2M | New |
| 2 | NTLA | Intellia Therapeutics, Inc. | $62.7M | 35.35% | 3.7M | Hold |
| 3 | ACET | Adicet Bio, Inc. | $522,819 | 0.30% | 60,511 | New |
| 4 | ACET | Adicet Bio, Inc. | $0 | 0.00% | 0 | Exited |
Source: SEC Form 13F filings · as of 2026-06-30
Every position in this 13F-HR, with its change from the prior quarter.
13F holdings, latest quarter
SourceSEC EDGAR13F-HR